Provenge (Sipuleucel-T)
By Business Review Editor
Pharma Deals Review: Vol 2007 Issue 79 (Table of Contents)
Published: 7 Jan-2007
DOI: 10.3833/pdr.v2007.i79.398 ISSN: 1756-7874
Section: Deal Trackers
Fulltext:
Abstract
Sipuleucel-T (APC8015) is Dendreon’s lead product and is an autologous dendritic cell-based vaccine, generated using the company’s proprietary technology, for the treatment of androgen independent and androgen-dependent prostate cancer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS